Vaccination against respiratory syncytial virus for adults over 60 is likely to be cost-effective by preventing illness, hospitalizations, lost quality of life and deaths, according to new research.
New RSV vaccine for older adults can result in individual and societal cost savings, benefits
-
HighlightsFree Dark Web Monitoring Stamps the $17 Million Credentials Markets
-
HighlightsSmart buildings: What happens to our free will when tech makes choices for us?
-
AppsScreenshots have generated new forms of storytelling, from Twitter fan fiction to desktop film
-
HighlightsDarknet markets generate millions in revenue selling stolen personal data, supply chain study finds
-
SecurityPrivacy violations undermine the trustworthiness of the Tim Hortons brand
-
Featured HeadlinesWhy Tesla’s Autopilot crashes spurred the feds to investigate driver-assist technologies – and what that means for the future of self-driving cars
